Cdk46 | List of Frontiers open access articles

Original Research

Published on 17 May 2022

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma

in Cancer Molecular Targets and Therapeutics

Orawan Suppramote
Sunisa Prasopporn
Satinee Aroonpruksakul
Ben Ponvilawan
Jiradej Makjaroen
Monthira Suntiparpluacha
Krittiya Korphaisarn
Komgrid Charngkaew
Rawisak Chanwat
Trairak Pisitkun

Frontiers in Oncology

doi 10.3389/fonc.2022.877194

7,806 views
17 citations

Original Research

Published on 05 Jan 2026

Genome-wide CRISPR screen identified NEK6 as a determinant of sensitivity to CDK4/6 inhibitor in endometrial cancer

in Pharmacology of Anti-Cancer Drugs

Fangfang Jian
Chongying Zhu
Yiwei Wang
Tianyu Zhou
Chenmin Yang
Weiwei Feng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1725886

1,801 views

Review

Published on 16 Nov 2020

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer

in Pharmacology of Anti-Cancer Drugs

Zhen Li
Wei Zou
Ji Zhang
Yunjiao Zhang
Qi Xu
Siyuan Li
Ceshi Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2020.580251

32,743 views
75 citations

Original Research

Published on 14 Jan 2022

The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer

in Cancer Immunity and Immunotherapy

Chen Liu
Yuhan Huang
Yaoyuan Cui
Jun Zhou
Xu Qin
Li Zhang
Xi Li
Yuan Li
Ensong Guo
Bin Yang

Frontiers in Immunology

doi 10.3389/fimmu.2021.799171

11,081 views
25 citations

Mini Review

Published on 23 Jul 2019

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

in Cancer Molecular Targets and Therapeutics

Amelia McCartney
Ilenia Migliaccio
Martina Bonechi
Chiara Biagioni
Dario Romagnoli
Francesca De Luca
Francesca Galardi
Emanuela Risi
Irene De Santo
Matteo Benelli

Frontiers in Oncology

doi 10.3389/fonc.2019.00666

45,389 views
162 citations

Review

Published on 22 Mar 2023

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective

in Cancer Cell Biology

Fiona H. Zhou
Teesha Downton
Allegra Freelander
Joshua Hurwitz
C. Elizabeth Caldon
Elgene Lim

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2023.1148792

38,254 views
51 citations

Mini Review

Published on 15 Apr 2020

Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

in Genomic Medicine

Giulia Occhipinti
Emanuela Romagnoli
Matteo Santoni
Alessia Cimadamore
Giulia Sorgentoni
Monia Cecati
Matteo Giulietti
Nicola Battelli
Alessandro Maccioni
Nadia Storti

Frontiers in Genetics

doi 10.3389/fgene.2020.00349

7,193 views
11 citations

Review

Accepted on 11 Jun 2026

Cyclin-dependent kinase 4/6 inhibitors in granulosa cell tumors and their combination with hormonal therapy: a scoping review

in Gynecological Oncology

Renata Pacholczak-Madej
Radosław Łupkowski
Karolina Górniak
Mirosława Puskulluoglu

Frontiers in Oncology

106 views

Mini Review

Published on 30 Jul 2021

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC

in Molecular and Cellular Oncology

Jinmeng Zhang
Dayu Xu
Yue Zhou
Zhengfei Zhu
Xi Yang

Frontiers in Oncology

doi 10.3389/fonc.2021.676041

10,238 views
43 citations

Original Research

Published on 08 Apr 2022

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma

in Pharmacology of Anti-Cancer Drugs

Ran Sun
Xuemei Wang
Leichao Zhang
Yu Gu
Shaojuan Yang
Liping Wang
Xueju Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.819003

3,596 views
2 citations

Review

Published on 31 May 2018

CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma

in Pediatric Oncology

Christine Hoeman
Chen Shen
Oren J. Becher

Frontiers in Oncology

doi 10.3389/fonc.2018.00191

8,227 views
21 citations

Original Research

Published on 01 Dec 2022

CDK4/6 inhibitor resistance: A bibliometric analysis

in Breast Cancer

Jiayuecheng Pang
Hengyu Li
Yuan Sheng

Frontiers in Oncology

doi 10.3389/fonc.2022.917707

7,890 views
8 citations

Original Research

Published on 06 Nov 2025

Ocular toxicity events of cyclin-dependent kinase 4/6 inhibitors in breast cancer: a pharmacovigilance study based on the faers database

in Pharmacology of Anti-Cancer Drugs

Mengdi Zhang
Dongqing Pu
Minmin Yu
Guangxi Shi
Jingwei Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1668446

3,811 views
1 citation

Review

Published on 12 Jul 2021

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

in Breast Cancer

Mridula A. George
Sadaf Qureshi
Coral Omene
Deborah L. Toppmeyer
Shridar Ganesan

Frontiers in Oncology

doi 10.3389/fonc.2021.693104

50,785 views
147 citations

Review

Published on 16 Jan 2024

Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer

in Breast Cancer

Cui Zhang
Fulin Zhou
Jiali Zou
Yanman Fang
Yuncong Liu
Libo Li
Jing Hou
Guanghui Wang
Hua Wang
Xiaolian Lai

Frontiers in Oncology

doi 10.3389/fonc.2023.1322078

11,242 views
10 citations

Review

Published on 22 Jul 2022

CDK 4/6 inhibitors for the treatment of meningioma

in Neuro-Oncology and Neurosurgical Oncology

Jacob S. Young
Reilly L. Kidwell
Allison Zheng
Alex F. Haddad
Manish K. Aghi
David R. Raleigh
Jessica D. Schulte
Nicholas A. Butowski

Frontiers in Oncology

doi 10.3389/fonc.2022.931371

8,420 views
20 citations

Articles

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma

Genome-wide CRISPR screen identified NEK6 as a determinant of sensitivity to CDK4/6 inhibitor in endometrial cancer

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer

The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective

Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

Cyclin-dependent kinase 4/6 inhibitors in granulosa cell tumors and their combination with hormonal therapy: a scoping review

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma

CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma

CDK4/6 inhibitor resistance: A bibliometric analysis

Ocular toxicity events of cyclin-dependent kinase 4/6 inhibitors in breast cancer: a pharmacovigilance study based on the faers database

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer

CDK 4/6 inhibitors for the treatment of meningioma